New ALS drug usnoflast faces crucial test in 240 patients
Disease control
Ongoing
This study tests whether the drug usnoflast can slow the progression of ALS, a serious nerve disease that weakens muscles over time. About 240 adults with ALS will receive either usnoflast or a placebo for 36 weeks. Researchers will measure changes in daily function and survival …
Phase: PHASE2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated May 01, 2026 21:57 UTC